Abstract
Abnormal epidermal growth factor receptor (EGFR) signaling is widespread in cancer, making the EGFR as an important target for therapy. The third-generation EGFR small-molecule inhibitors are at the forefront clinically for treatment of patients with non-small cell lung cancer (NSCLC). However, acquired resistance limits the effectiveness. The c-Jun N-terminal kinase (JNK) signaling axis mediates primary resistance to EGFR inhibition in glioblastoma (GBM) and NSCLC. Therefore, it's a new approach of using a dual EGFR and JNK inhibition to treat EGFR-expressing GBM and NSCLC is a new approach. On the basis of an iterative approach of docking, two series of trisubstituted 1,2,4-triazoles and thiazoles were designed and synthesized. Some compounds demonstrated inhibitory activity for EGFR and JNK kinases with IC50 values in the low nanomolar range. This work may lead to design and optimize the potent EGFR and JNK inhibitors in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
